-
Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel JF, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD New England Journal of Medicine 357(21):2123-32 FI: 47.050 (Q1) New criteria to identify risk of progression in monoclonal gammopathy uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells Pérez-Persona E, Vidriales MB, Mateo G, García-Sanz R, Mateos MV, de Coca AG, Galende J, Martín-Núñez G, Alonso JM, de Las Heras N, Hernández JM, Martín A, López-Berges C, Orfao A, San Miguel JF Blood 110(7):2586-92 FI: 10.555 (Q1) Novel etodolacanalog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S, Okawa Y, Neri P, Sukhdeo K, Podar K, Chauhan D, Richardson PG, Raje N, Carrasco DR, Anderson KC Leukemia 21(3):535-40 FI: 8.296 (Q1) Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis Ramirez JM, Ocio EM, San Miguel JF, Pandiella A Leukemia 21(4):797-804 FI: 8.296 (Q1) Phase II PETHEMA trial of alternating Bortezomib and Dexamethasone as induction regimen before autologous stem cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics Rosinol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutierrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel JF, Bladé J Journal of Clinical Oncology 25(28):4452-8 FI: 17.793 (Q1) Prognostic factors and staging in multiple myeloma Fonseca R, San Miguel JF Hematology/ Oncology Clinics of North America 21(6):1115-40 FI: 2.054 (Q3) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel JF, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL Journal of Clinical Oncology 25(25):3892-901 FI: 17.793 (Q1) Safety and efficacy of bortezomib in high ¿risk and elderly patients with relapsed multiple myeloma Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Ehud D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC British Journal of Haematology 137(5):429-35 FI: 4.597 (Q1) Spanish Myeloma Group/ PETHEMA. Veno-occlusive disease of the liver after high dose cytoreductive therapy with busulfan and melphalna for autologous blood stem cell transplantation in multiple myeloma patients Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel JF, Bladé J, Lahuerta JJ Biology of Blood and Marrow Transplantation 13(12):1448-54 FI: 3.149 (Q2) The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib Armand JP, Burnett A.K, Drach J, Harousseau JL, Lowenberg B, San Miguel JF 12(3):281-90 FI: 6.701 (Q1)
|
